Tuesday, March 30, 2010 10:59:10 AM
"China Medicine expects the acquisition to be accretive to earnings generating revenues of between $10.0 million and $12.0 million and net profit margin of at least 40% in 2010"
You see what the problem is? They now reduced the expectation from 10 - 12 mil and net margin at least 40% to 6 -8 mil and gross margin 40%. I hope they mean net margin because 40% GM is low for a self brand drug. I heard they mentioned "limited production" also but have no idea what it means.
Also, the end of the year radtz approval is their guess. They have no idea how long does it take only hope it won't be too long.
Now, about the "reformatting the data". My fear is that MOA is not satisfied with their trial run data and want more evidence even though they think they have enough.
From top to bottom, this is a disappointing report and CC.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM